RT Journal Article
SR Electronic
T1 Whole-exome sequencing analysis on products of conception: A cohort study to evaluate clinical utility and genetic etiology for pregnancy loss
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.19.20150144
DO 10.1101/2020.07.19.20150144
A1 Zhao, Chen
A1 Chai, Hongyan
A1 Zhou, Qinghua
A1 Wen, Jiadi
A1 Reddy, Uma M.
A1 Kastury, Rama
A1 Jiang, Yonghui
A1 Mak, Winifred
A1 Bale, Allen E.
A1 Zhang, Hui
A1 Li, Peining
YR 2020
UL http://medrxiv.org/content/early/2020/07/20/2020.07.19.20150144.abstract
AB Purpose Pregnancy loss ranging from spontaneous abortion (SAB) to stillbirth can result from monogenic causes of Mendelian inheritance. This study evaluated the clinical application of whole exome sequencing (WES) in identifying the genetic etiology for pregnancy loss.Methods A cohort of 102 specimens from products of conception (POC) with normal karyotype and absence of pathogenic copy number variants were selected for WES. Abnormality detection rate (ADR) and variants of diagnostic value correlated with SAB and stillbirth were evaluated.Results WES detected six pathogenic variants, 16 likely pathogenic variants, and 17 variants of uncertain significance favor pathogenic (VUSfp) from this cohort. The ADR for pathogenic and likely pathogenic variants was 22% and reached 35% with the inclusion of VUSfp. The ADRs of SAB and stillbirth were 36% and 33%, respectively. Affected genes included those associated with multi-system abnormalities, neurodevelopmental disorders, cardiac anomalies, skeletal dysplasia, metabolic disorders and renal diseases.Conclusion These results supported the clinical utility of WES for detecting monogenic etiology of pregnancy loss. The identification of disease associated variants provided information for follow-up genetic counseling of recurrence risk and management of subsequent pregnancies. Discovery of novel variants could provide insight for underlying molecular mechanisms causing fetal death.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNot applicableFunding Statementnot applicableAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:In the ethics statement at the section of materials and methods: This study used surplus DNA from POC samples with no personally identifiable private information, it was deemed exempt from ethical oversight and human subject regulations by Yale University Institutional Review Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe online version of this article contains supplementary figure S1 and supplementary tables S1, S2 and S3.